Divis Laboratories Ltd Share Price (DIVISLAB)

Analysts Upgrade Divis Labs Rating and Target Price - 04 Apr, 2024

Divis Laboratories Ltd sees positive momentum as DRChoksey initiates coverage with an 'Accumulate' rating, while BofA Securities upgrades it to Buy from Underperform with a revised target price of Rs 4,025. The stock has gained for five consecutive sessions.

Divis Labs Upgraded by BofA Securities - 03 Apr, 2024

Global brokerage BofA Securities upgraded Divis Laboratories to buy from underperform and raised the target price to Rs 4,025 apiece due to its improving earnings outlook. KR Chokseys initiated coverage on the stock with an accumulate rating and a target price of Rs 3,931. The pharma company reported a Q3 FY24 net profit of Rs 358 crore, up 17% YoY.

Divis Laboratories Ltd Up 1.51% on NSE - 02 Apr, 2024

Divis Laboratories Ltd is up 1.51% on the NSE, trading at Rs 3622 as of 12:49 IST. The stock has gained 26% in the last year compared to a 28.88% gain in NIFTY and a 58.71% gain in the Nifty Pharma index.

Divis Labs to Build New Factory in Andhra Pradesh - 01 Apr, 2024

Divis Laboratories is investing ₹1,200-1,500 crore in the first phase of building a new factory over 500 acres in Kona, Kakinada. The company reported revenues of ₹7,974 crore in FY23.

Divis Laboratories Insiders Sell Significant Stake - 26 Mar, 2024

Over the past year, Divis Laboratories insiders have sold a significant stake in the company. In the last three months alone, insiders sold ₹302m worth of shares without any purchases recorded. While high insider ownership is good, the selling leaves investors cautious.

Divis Laboratories Ltd Gains for Fifth Straight Session - 12 Mar, 2024

Divis Laboratories Ltd stock is up 0.23% on the NSE, quoting at Rs 3613.2 as of 12:44 IST. The benchmark NIFTY is up around 0.21%, while Sensex is up 0.37%. The stock has slipped around 2.36% in the last one month with a PE ratio of 70.16 based on TTM earnings ending December 23.

Divis Laboratories Founder Among World's Richest Scientists - 10 Mar, 2024

Murali Divi, founder of Divis Laboratories, is among the richest scientists in the world with a net worth of approximately Rs 51306 crore as per Forbes. Divis Laboratories is a top-three manufacturer of active pharmaceutical ingredients (API) with a market capitalization of nearly Rs 955 billion.

Divis Laboratories Ltd Up 1.28% on NSE - 07 Mar, 2024

Divis Laboratories Ltd gained for a third straight session, up 1.28% to Rs 3590.05 on the NSE. The stock has slipped around 2.56% in the last month but is up 26.66% in the last year. The PE of the stock is 69 based on TTM earnings ending December 23.